FATE
Fate Therapeutics Inc
Price:  
6.88 
USD
Volume:  
1,941,091.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

FATE EV/EBITDA

-616.6%
Upside

As of 2024-02-23, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -2.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 507.50 mil USD. FATE's TTM EBITDA according to its financial statements is -178.92 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 12.0x - 15.7x 13.1x
Forward P/E multiples 17.4x - 19.4x 18.5x
Fair Price (39.23) - (35.22) (35.54)
Upside -670.2% - -611.9% -616.6%
6.88 USD
Stock Price
(35.54) USD
Fair Price

FATE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-02-22 -3.12
2024-02-21 -3.10
2024-02-20 -3.20
2024-02-16 -3.43
2024-02-15 -3.21
2024-02-14 -2.95
2024-02-13 -2.90
2024-02-12 -3.11
2024-02-09 -2.86
2024-02-08 -2.77
2024-02-07 -2.52
2024-02-06 -2.61
2024-02-05 -2.89
2024-02-02 -2.96
2024-02-01 -3.07
2024-01-31 -2.80
2024-01-30 -2.53
2024-01-29 -2.60
2024-01-26 -2.07
2024-01-25 -2.07
2024-01-24 -2.09
2024-01-23 -2.19
2024-01-22 -2.14
2024-01-19 -2.06
2024-01-18 -1.97
2024-01-17 -2.00
2024-01-16 -2.05
2024-01-12 -2.07
2024-01-11 -2.02
2024-01-10 -2.07
2024-01-09 -2.00
2024-01-08 -1.87
2024-01-05 -1.71
2024-01-04 -1.74
2024-01-03 -1.61
2024-01-02 -1.67
2023-12-29 -1.70
2023-12-28 -1.79
2023-12-27 -1.66
2023-12-26 -1.69
2023-12-22 -1.55
2023-12-21 -1.52
2023-12-20 -1.39
2023-12-19 -1.49
2023-12-18 -1.43
2023-12-15 -1.37
2023-12-14 -1.35
2023-12-13 -1.22
2023-12-12 -1.09
2023-12-11 -1.03